Evidence map›Paper›PMID 22366654›Full record

ArticleBioorganic & medicinal chemistry letters2012

2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.

Archna P Massey, William R Harley, NagaRekha Pasupuleti, Fredric A Gorin, Michael H Nantz

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Small molecule-RNA targeting: starting with the fundamentals.Chemical communications (Cambridge, England) · 2020
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Archna P MasseyDepartment of Chemistry, University of Louisville, Louisville, KY 40292, USA.
William R Harley
NagaRekha Pasupuleti
Fredric A Gorin
Michael H Nantz
University of California, Davis · USUniversity of Louisville · US

Funding

Novel Amiloride Conjugates Selectively Kill GliomasR01NS040489 · NINDS · UNIVERSITY OF CALIFORNIA DAVIS · PI GORIN, FREDRIC A · 2001 to 2007
$1.7M
Novel Glioma uPA Inhibitor Design Guided by Intracellular signaling PathwaysR01NS060880 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI GORIN, FREDRIC A · 2009 to 2010
$744k
NINDS NIH HHS NS040489NINDS NIH HHS NS060880NINDS NIH HHS R01 NS040489NINDS NIH HHS R01 NS060880
6 · The paper itself

Abstract

The relative non-toxicity of the diuretic amiloride, coupled with its selective inhibition of the protease urokinase plasminogen activator (uPA), makes this compound class attractive for structure-activity studies. Herein we substituted the C(2)-acylguanidine of C(5)-glycyl-amiloride with amidine and amidoxime groups. The data show the importance of maintaining C(5)-hydrophobicity. The C(5)-benzylglycine analogs containing either C(2)-acylguanidine or amidine inhibited uPA with an IC(50) ranging from 3 to 7 μM and were cytotoxic to human U87 malignant glioma cells.

Indexed as

AmidinesAmilorideAntineoplastic AgentsCell Line, TumorCell SurvivalDrug Screening Assays, AntitumorGlycineHumansHydrophobic and Hydrophilic InteractionsSerine Proteinase InhibitorsStructure-Activity RelationshipTissue Plasminogen ActivatorUrokinase-Type Plasminogen ActivatorAmidinesAmilorideAntineoplastic AgentsGlycineSerine Proteinase InhibitorsTissue Plasminogen ActivatorUrokinase-Type Plasminogen Activator

Identifiers

PMID22366654
PMCPMC3329872
OpenAlexW1984028237

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.